Publications by authors named "Jessica Encinas Mayoral"
Article Synopsis
- CDK7 is essential for the growth of multiple myeloma (MM) cells, as it regulates critical programs like E2F and MYC, which are linked to cell survival and metabolism.
- Targeting CDK7 with a specific inhibitor (YKL-5-124) not only disrupts these oncogenic pathways but also shows strong anti-tumor effects with minimal harm to normal cells, leading to reduced glycolysis and lactate production in MM cells.
- The promising results from mouse models highlight CDK7 as a key player in MM progression and suggest that YKL-5-124 could be an effective treatment option worth pursuing in clinical settings.
Multiple myeloma (MM) is characterized by an immunosuppressive microenvironment that enables tumor development. One of the mechanisms of immune evasion used by MM cells is the inhibition of natural killer (NK) cell effector functions; thus, the restoration of NK cell antitumor activity represents a key goal to increase tumor cell recognition, avoid tumor escape and potentially enhancing the effect of other drugs. In this study, we evaluated the ability of the investigational medicine NKTR-255, an IL-15 receptor agonist, to engage the IL-15 pathway and stimulate NK cells against MM cells.
View Article and Find Full Text PDF